Eledon Pharmaceuticals announces updated data from tegoprubart trial
Trial Results: Eledon Pharmaceuticals presented updated data from their Phase 1b trial of tegoprubart for kidney transplant patients, showing stabilized kidney function and promising graft survival rates compared to standard care.
Safety and Future Studies: Tegoprubart was well-tolerated with no severe side effects reported, and the company is conducting further trials, including a Phase 2 study with results expected in November 2025.
Trade with 70% Backtested Accuracy
Analyst Views on ELDN
About ELDN
About the author
Eledon Pharmaceuticals Presents 24-Month Data on Tegoprubart, Showing Significant eGFR Improvement
- Clinical Trial Results: Eledon presented 24-month follow-up data from eight patients at the 2026 American Society of Transplant Surgeons Winter Symposium, showing a significant increase in eGFR from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m², indicating the potential efficacy of tegoprubart in kidney transplantation.
- Safety Assessment: Throughout the study, there were no episodes of biopsy-proven acute rejection, graft loss, death, or new-onset diabetes, further validating the safety and tolerability of tegoprubart, which enhances its market prospects.
- Academic Presentation Schedule: The study's poster will be presented during the poster session on January 23, 2026, from 5:45 to 7:15 PM, providing attendees with an opportunity to gain deeper insights into the drug, potentially attracting investor interest.
- Company Background: Eledon is a clinical-stage biotechnology company focused on developing immune-modulating therapies, with tegoprubart as its lead candidate, targeting CD40L's high affinity, which offers broad therapeutic potential in areas such as kidney transplantation.
Avant Technologies Achieves 83% Insulin Independence Rate, Driving Investment Shift
- Clinical Trial Success: Avant Technologies achieved an 83% insulin independence rate in recent clinical trials, marking a significant shift towards functional cures that has attracted investment interest from the pharmaceutical industry, driving record valuations in 2025 M&A activity.
- Massive Market Potential: Analysts project the regenerative medicine market will surge from $37.98 billion in 2025 to $88.85 billion by 2030, highlighting strong demand for curative cell therapies, with Avant Technologies positioned at the forefront of this growth wave.
- Technological Breakthrough: Avant's collaboration with SGAustria to develop cell encapsulation technology protects genetically modified insulin-producing cells from immune rejection, addressing the long-standing issue of patients' reliance on immunosuppressive drugs, thereby enhancing treatment safety and efficacy.
- Global Health Market Opportunity: With 589 million people globally living with type 1 and insulin-dependent type 2 diabetes, projected to reach 853 million by 2050, Avant's technology is poised to capture a significant share of this vast market, driving future growth for the company.
Avant Technologies Achieves 83% Insulin Independence Rate, Driving Metabolic Disease Investment
- Clinical Trial Success: Avant Technologies has achieved an 83% insulin independence rate in recent clinical trials, marking a significant shift towards functional cures and attracting substantial investment interest in the metabolic disease sector, which is expected to enhance the company's market share.
- Surge in M&A Activity: Late 2025 saw record M&A activity as major pharmaceutical companies raced to acquire curative platforms, indicating a diminishing focus on symptom management, positioning Avant Technologies advantageously in a rapidly evolving market landscape.
- Massive Market Potential: Analysts project the regenerative medicine market will grow from $37.98 billion in 2025 to $88.85 billion by 2030, creating expansive business opportunities for Avant Technologies, particularly in diabetes and aging therapies.
- Technological Innovation: Through its partnership with SGAustria, Avant Technologies is developing cell encapsulation technology that addresses immune rejection issues, which is expected to significantly improve patient quality of life and provide safe, scalable solutions for diabetes treatment.
Biotech Sector Sustains After-Hours Trading Gains
Market Activity: Several small- and mid-cap stocks experienced notable gains in after-hours trading, driven by investor sentiment and sector momentum rather than new company news.
Top Gainers: Spyre Therapeutics, Inc. (SYRE) led the gains with a 4.99% increase, followed by The Oncology Institute, Inc. (TOI) with a 5.49% rise, both without any fresh updates.
Sector Trends: Aurora Cannabis Inc. (ACB) and Lexeo Therapeutics, Inc. (LXEO) also saw gains, benefiting from renewed momentum in the cannabis and biotech sectors, respectively, despite no new announcements.
Significant Developments: Solid Biosciences Inc. (SLDB) recently highlighted a key milestone regarding Duchenne muscular dystrophy, which has positively influenced its stock performance, even without new news on the trading day.
Eledon Pharmaceuticals Reports GAAP EPS of -$0.21
Q3 Financial Performance: Eledon Pharmaceuticals reported a Q3 GAAP EPS of -$0.21, indicating a loss for the quarter.
Cash Position: As of September 30, 2025, the company had $93.4 million in cash, cash equivalents, and short-term investments, down from $140.2 million at the end of 2024.
Stock Movement: The company's stock dropped by 10% following a recent stock offering.
Clinical Trial Updates: Eledon Pharmaceuticals discussed the results of its Phase II BESTOW trial and advancements in transplantation immunosuppression.
Eledon Pharmaceuticals' Key Asset Falls Short in Mid-Stage Trial, Yet Advances to Crucial Study
Stock Performance: Eledon Pharmaceuticals (NASDAQ: ELDN) experienced a significant drop in stock price, down 59.03% to $1.68, with a trading volume of 15.72 million shares compared to its average of 1.24 million.
Phase 2 Trial Results: The Phase 2 BESTOW trial for tegoprubart, aimed at preventing organ rejection in kidney transplant patients, did not show significant improvements in estimated glomerular filtration rates (eGFR) compared to the standard immunosuppressant tacrolimus.
Efficacy and Safety Findings: Despite missing the primary efficacy endpoint, tegoprubart demonstrated the highest mean eGFR reported in kidney transplant trials and showed lower rates of delayed graft function and shorter dialysis duration compared to tacrolimus.
Future Development Plans: Eledon plans to advance tegoprubart into Phase 3 development after discussions with regulators, supported by approximately $93.4 million in cash reserves expected to last until late 2026.
Eledon Pharmaceuticals Presents 24-Month Data on Tegoprubart, Showing Significant eGFR Improvement
- Clinical Trial Results: Eledon presented 24-month follow-up data from eight patients at the 2026 American Society of Transplant Surgeons Winter Symposium, showing a significant increase in eGFR from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m², indicating the potential efficacy of tegoprubart in kidney transplantation.
- Safety Assessment: Throughout the study, there were no episodes of biopsy-proven acute rejection, graft loss, death, or new-onset diabetes, further validating the safety and tolerability of tegoprubart, which enhances its market prospects.
- Academic Presentation Schedule: The study's poster will be presented during the poster session on January 23, 2026, from 5:45 to 7:15 PM, providing attendees with an opportunity to gain deeper insights into the drug, potentially attracting investor interest.
- Company Background: Eledon is a clinical-stage biotechnology company focused on developing immune-modulating therapies, with tegoprubart as its lead candidate, targeting CD40L's high affinity, which offers broad therapeutic potential in areas such as kidney transplantation.
Avant Technologies Achieves 83% Insulin Independence Rate, Driving Investment Shift
- Clinical Trial Success: Avant Technologies achieved an 83% insulin independence rate in recent clinical trials, marking a significant shift towards functional cures that has attracted investment interest from the pharmaceutical industry, driving record valuations in 2025 M&A activity.
- Massive Market Potential: Analysts project the regenerative medicine market will surge from $37.98 billion in 2025 to $88.85 billion by 2030, highlighting strong demand for curative cell therapies, with Avant Technologies positioned at the forefront of this growth wave.
- Technological Breakthrough: Avant's collaboration with SGAustria to develop cell encapsulation technology protects genetically modified insulin-producing cells from immune rejection, addressing the long-standing issue of patients' reliance on immunosuppressive drugs, thereby enhancing treatment safety and efficacy.
- Global Health Market Opportunity: With 589 million people globally living with type 1 and insulin-dependent type 2 diabetes, projected to reach 853 million by 2050, Avant's technology is poised to capture a significant share of this vast market, driving future growth for the company.
Avant Technologies Achieves 83% Insulin Independence Rate, Driving Metabolic Disease Investment
- Clinical Trial Success: Avant Technologies has achieved an 83% insulin independence rate in recent clinical trials, marking a significant shift towards functional cures and attracting substantial investment interest in the metabolic disease sector, which is expected to enhance the company's market share.
- Surge in M&A Activity: Late 2025 saw record M&A activity as major pharmaceutical companies raced to acquire curative platforms, indicating a diminishing focus on symptom management, positioning Avant Technologies advantageously in a rapidly evolving market landscape.
- Massive Market Potential: Analysts project the regenerative medicine market will grow from $37.98 billion in 2025 to $88.85 billion by 2030, creating expansive business opportunities for Avant Technologies, particularly in diabetes and aging therapies.
- Technological Innovation: Through its partnership with SGAustria, Avant Technologies is developing cell encapsulation technology that addresses immune rejection issues, which is expected to significantly improve patient quality of life and provide safe, scalable solutions for diabetes treatment.
Biotech Sector Sustains After-Hours Trading Gains
Market Activity: Several small- and mid-cap stocks experienced notable gains in after-hours trading, driven by investor sentiment and sector momentum rather than new company news.
Top Gainers: Spyre Therapeutics, Inc. (SYRE) led the gains with a 4.99% increase, followed by The Oncology Institute, Inc. (TOI) with a 5.49% rise, both without any fresh updates.
Sector Trends: Aurora Cannabis Inc. (ACB) and Lexeo Therapeutics, Inc. (LXEO) also saw gains, benefiting from renewed momentum in the cannabis and biotech sectors, respectively, despite no new announcements.
Significant Developments: Solid Biosciences Inc. (SLDB) recently highlighted a key milestone regarding Duchenne muscular dystrophy, which has positively influenced its stock performance, even without new news on the trading day.
Eledon Pharmaceuticals Reports GAAP EPS of -$0.21
Q3 Financial Performance: Eledon Pharmaceuticals reported a Q3 GAAP EPS of -$0.21, indicating a loss for the quarter.
Cash Position: As of September 30, 2025, the company had $93.4 million in cash, cash equivalents, and short-term investments, down from $140.2 million at the end of 2024.
Stock Movement: The company's stock dropped by 10% following a recent stock offering.
Clinical Trial Updates: Eledon Pharmaceuticals discussed the results of its Phase II BESTOW trial and advancements in transplantation immunosuppression.
Eledon Pharmaceuticals' Key Asset Falls Short in Mid-Stage Trial, Yet Advances to Crucial Study
Stock Performance: Eledon Pharmaceuticals (NASDAQ: ELDN) experienced a significant drop in stock price, down 59.03% to $1.68, with a trading volume of 15.72 million shares compared to its average of 1.24 million.
Phase 2 Trial Results: The Phase 2 BESTOW trial for tegoprubart, aimed at preventing organ rejection in kidney transplant patients, did not show significant improvements in estimated glomerular filtration rates (eGFR) compared to the standard immunosuppressant tacrolimus.
Efficacy and Safety Findings: Despite missing the primary efficacy endpoint, tegoprubart demonstrated the highest mean eGFR reported in kidney transplant trials and showed lower rates of delayed graft function and shorter dialysis duration compared to tacrolimus.
Future Development Plans: Eledon plans to advance tegoprubart into Phase 3 development after discussions with regulators, supported by approximately $93.4 million in cash reserves expected to last until late 2026.
